Endurant CHevAr New Indication Trial: ENCHANT

Inclusion Criteria: * Subject is ≥18 years old * Subject is scheduled for primary treatment of the juxtarenal aortic aneurysm with a short infrarenal neck (i.e. no revision subjects) * Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements * Subject has provided written informed consent * Subject is an eligible candidate according to the currently available Endurant II/IIs instructions for use for ChEVAR * Subject has a juxtarenal aortic aneurysm with a short infrarenal neck (definition of juxtarenal aortic aneurysm with a short infrarenal neck will be in accordance with commercially available Endurant II/IIs instructions for use for ChEVAR). Exclusion Criteria: * Subject is participating in a concurrent study which may confound study results * Subject has a life expectancy ≤ 2 year * Subject has an aneurysm that is: * Suprarenal or pararenal * Isolated iliofemoral * Mycotic * Inflammatory * Pseudoaneurysm * Subject requires emergent aneurysm treatment, for example, trauma or rupture * Subject has previously undergone surgical treatment for abdominal aortic aneurysm * Subject is a female of childbearing potential in whom pregnancy cannot be excluded * Subject has a known hypersensitivity or contraindication to anticoagulants, anti-platelets, or contrast media, which is not amenable to pre-treatment * Subject has a creatinine level \>2.0 mg/dl (or \>176.8 μmol/L) and/or is on dialysis * Subject has an active COVID-19 infection or relevant history of COVID-19. Relevant history of COVID-19 is defined as availability of a positive COVID-19 test with sequela or hospitalization for treatment of COVID-19. Subjects with a positive COVID-19 test who were asymptomatic or had mild symptoms should be excluded only if the positive test was less than 6 months prior to enrollment